Covaxin Shows 50% Effectiveness Against Symptomatic COVID-19, Says Study Published In Lancet

Two doses of Covaxin are 50 per cent effective against symptomatic disease, according to the first real-world assessment of India's indigenous COVID-19 vaccine published in The Lancet Infectious Diseases journal. Results of an interim study recently published in The Lancet showed that two doses of Covaxin, also known as BBV152, had 77.8 per cent efficacy against symptomatic disease and present no serious safety concerns.

from Top India News-
Read The Rest:news18..